Go Pro

Certara (CERT) Competitors

Certara logo
$8.35 -0.06 (-0.71%)
As of 08/28/2026 04:00 PM Eastern

CERT vs. WAY, DOCS, HTFL, SDGR, and GDRX

Should you buy Certara stock or one of its competitors? Certara's main competitors and comparable companies include Waystar (WAY), Doximity (DOCS), Heartflow (HTFL), Schrodinger (SDGR), and GoodRx (GDRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Certara compare to Waystar?

Certara (NASDAQ:CERT) and Waystar (NASDAQ:WAY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

74.0% of Certara shares are held by institutional investors. 1.1% of Certara shares are held by company insiders. Comparatively, 3.5% of Waystar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Waystar has a net margin of 11.18% compared to Certara's net margin of -16.75%. Waystar's return on equity of 7.03% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.75% 3.86% 2.65%
Waystar 11.18%7.03%4.75%

Certara presently has a consensus price target of $8.28, indicating a potential downside of 0.86%. Waystar has a consensus price target of $35.39, indicating a potential upside of 34.88%. Given Waystar's stronger consensus rating and higher possible upside, analysts plainly believe Waystar is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.42
Waystar
1 Sell rating(s)
2 Hold rating(s)
20 Buy rating(s)
3 Strong Buy rating(s)
2.96

Waystar has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Waystar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$421.75M3.02-$1.60M-$0.45N/A
Waystar$1.21B4.17$112.09M$0.7037.49

Certara has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Waystar has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

In the previous week, Waystar had 22 more articles in the media than Certara. MarketBeat recorded 26 mentions for Waystar and 4 mentions for Certara. Certara's average media sentiment score of 1.78 beat Waystar's score of 0.84 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Waystar
13 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Waystar beats Certara on 14 of the 17 factors compared between the two stocks.

How does Certara compare to Doximity?

Certara (NASDAQ:CERT) and Doximity (NYSE:DOCS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Certara currently has a consensus price target of $8.28, suggesting a potential downside of 0.86%. Doximity has a consensus price target of $32.43, suggesting a potential upside of 21.27%. Given Doximity's higher probable upside, analysts plainly believe Doximity is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.42
Doximity
4 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.28

Doximity has a net margin of 25.48% compared to Certara's net margin of -16.75%. Doximity's return on equity of 18.06% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.75% 3.86% 2.65%
Doximity 25.48%18.06%15.40%

In the previous week, Doximity had 6 more articles in the media than Certara. MarketBeat recorded 10 mentions for Doximity and 4 mentions for Certara. Certara's average media sentiment score of 1.78 beat Doximity's score of 0.65 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Doximity
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Certara has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Doximity has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Doximity has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$421.75M3.02-$1.60M-$0.45N/A
Doximity$644.86M7.39$196.05M$0.8531.46

74.0% of Certara shares are held by institutional investors. Comparatively, 87.2% of Doximity shares are held by institutional investors. 1.1% of Certara shares are held by company insiders. Comparatively, 31.8% of Doximity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Doximity beats Certara on 14 of the 17 factors compared between the two stocks.

How does Certara compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Certara (NASDAQ:CERT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Certara has a net margin of -16.75% compared to Heartflow's net margin of -55.82%. Certara's return on equity of 3.86% beat Heartflow's return on equity.

Company Net Margins Return on Equity Return on Assets
Heartflow-55.82% -23.52% -18.66%
Certara -16.75%3.86%2.65%

Heartflow presently has a consensus price target of $43.43, suggesting a potential downside of 9.11%. Certara has a consensus price target of $8.28, suggesting a potential downside of 0.86%. Given Certara's higher probable upside, analysts plainly believe Certara is more favorable than Heartflow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heartflow
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Certara
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.42

Certara has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Certara, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heartflow$176.03M23.60-$116.79M-$1.83N/A
Certara$421.75M3.02-$1.60M-$0.45N/A

In the previous week, Heartflow had 11 more articles in the media than Certara. MarketBeat recorded 15 mentions for Heartflow and 4 mentions for Certara. Certara's average media sentiment score of 1.78 beat Heartflow's score of 1.10 indicating that Certara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heartflow
10 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Certara
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

74.0% of Certara shares are owned by institutional investors. 7.7% of Heartflow shares are owned by insiders. Comparatively, 1.1% of Certara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Certara beats Heartflow on 10 of the 15 factors compared between the two stocks.

How does Certara compare to Schrodinger?

Certara (NASDAQ:CERT) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Certara has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Certara, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$421.75M3.02-$1.60M-$0.45N/A
Schrodinger$259.04M5.61-$103.26M-$0.74N/A

Certara has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

74.0% of Certara shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 1.1% of Certara shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Certara has a net margin of -16.75% compared to Schrodinger's net margin of -20.98%. Certara's return on equity of 3.86% beat Schrodinger's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.75% 3.86% 2.65%
Schrodinger -20.98%-16.37%-8.19%

Certara presently has a consensus price target of $8.28, indicating a potential downside of 0.86%. Schrodinger has a consensus price target of $20.50, indicating a potential upside of 4.06%. Given Schrodinger's higher probable upside, analysts clearly believe Schrodinger is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.42
Schrodinger
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

In the previous week, Schrodinger had 4 more articles in the media than Certara. MarketBeat recorded 8 mentions for Schrodinger and 4 mentions for Certara. Certara's average media sentiment score of 1.78 beat Schrodinger's score of 1.18 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Schrodinger
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Certara beats Schrodinger on 11 of the 17 factors compared between the two stocks.

How does Certara compare to GoodRx?

Certara (NASDAQ:CERT) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Certara presently has a consensus target price of $8.28, indicating a potential downside of 0.86%. GoodRx has a consensus target price of $4.23, indicating a potential upside of 19.75%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.42
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08

74.0% of Certara shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 1.1% of Certara shares are held by company insiders. Comparatively, 5.9% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GoodRx has a net margin of 2.07% compared to Certara's net margin of -16.75%. GoodRx's return on equity of 7.22% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.75% 3.86% 2.65%
GoodRx 2.07%7.22%2.53%

Certara has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, GoodRx had 6 more articles in the media than Certara. MarketBeat recorded 10 mentions for GoodRx and 4 mentions for Certara. Certara's average media sentiment score of 1.78 beat GoodRx's score of 0.44 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
GoodRx
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GoodRx has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$421.75M3.02-$1.60M-$0.45N/A
GoodRx$785.23M1.54$30.44M$0.0488.25

Summary

GoodRx beats Certara on 10 of the 16 factors compared between the two stocks.

Get Certara News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERT vs. The Competition

MetricCertaraHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.27B$1.79B$7.20B$12.90B
Dividend YieldN/A4.68%2.54%11.28%
P/E Ratio-18.5621.60273.1625.45
Price / Sales3.0286.89604.8776.92
Price / Cash11.0431.9376.7453.00
Price / Book1.327.4912.986.14
Net Income-$1.60M-$18.66M$3.48B$348.86M
7 Day Performance-0.95%2.40%0.13%-0.80%
1 Month Performance7.33%15.25%7.08%4.13%
1 Year Performance-22.97%-14.96%24.67%15.17%

Certara Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERT
Certara
1.8236 of 5 stars
$8.35
-0.7%
$8.28
-0.9%
-23.0%$1.27B$421.75MN/A1,576
WAY
Waystar
4.4703 of 5 stars
$25.35
+1.4%
$35.00
+38.1%
-30.7%$4.80B$1.10B36.211,700
DOCS
Doximity
4.694 of 5 stars
$25.25
-0.3%
$32.43
+28.4%
N/A$4.51B$644.86M29.71890
HTFL
Heartflow
2.1584 of 5 stars
$50.20
+0.9%
$43.43
-13.5%
+51.7%$4.33B$212.07MN/A699
SDGR
Schrodinger
1.3087 of 5 stars
$18.77
-4.8%
$20.50
+9.2%
+1.0%$1.46B$255.87MN/A790

Related Companies and Tools


This page (NASDAQ:CERT) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners